Discovery and characterization of potent small molecule inhibitors of the high affinity proline transporter
The mammalian proline transporter (PROT) is a high affinity Na +/Cl −-dependent transporter expressed in specific regions of the brain. It is homologous to other neurotransmitter transporters such as glycine, norepinephrine, serotonin, and dopamine transporters. PROT is enriched in glutamatergic syn...
Saved in:
Published in | Neuroscience letters Vol. 451; no. 3; pp. 212 - 216 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Shannon
Elsevier Ireland Ltd
27.02.2009
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The mammalian proline transporter (PROT) is a high affinity Na
+/Cl
−-dependent transporter expressed in specific regions of the brain. It is homologous to other neurotransmitter transporters such as glycine, norepinephrine, serotonin, and dopamine transporters. PROT is enriched in glutamatergic synaptic terminals and may play an important role in the regulation of excitatory neurotransmission. No non-peptide small molecule inhibitors have been described for this transporter. To study its physiological role in the central nervous system and evaluate its potential as a therapeutic target, we established cell lines that stably express recombinant hPROT and characterized its kinetic properties for proline uptake. We then screened for inhibitors and identified a series of compounds that inhibit hPROT-mediated proline uptake. A known compound, benztropine, was found to inhibit hPROT with an IC
50 of 0.75
μM. A series of novel compounds were also found, one of which, LP-403812, showed an IC
50 of approximately 0.1
μM on both recombinant human and mouse PROT without significant inhibition of glycine and dopamine transporters at concentrations up to 10
μM. This compound also inhibited proline transporter activity of mouse brain synaptosomes with the same potency. These inhibitors provide important tools for the understanding of PROT functions in the brain and may lead to the development of therapeutic agents for certain neurological disorders. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
ISSN: | 0304-3940 1872-7972 |
DOI: | 10.1016/j.neulet.2009.01.018 |